Physician profile
Ramzi Abboud
NPI 1649684200
$3,880.33
in general payments reported to CMS, 2019-2025
9 companies · $49.90 in 2025
The $49.90 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2023: $3,442 · 2024: $94.12 · 2025: $49.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,055 · Travel and Lodging: $1,124 · Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,055.00 |
| Travel and Lodging | $1,123.97 |
| Food and Beverage | $407.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $2,139.71 | 2023 | Tavalisse, Rezlidhia |
| Incyte Corporation | $1,322.93 | 2023-2025 | Jakafi |
| Astellas Pharma US INC | $198.99 | 2019 | |
| Amgen INC. | $95.00 | 2019 | |
| Abbvie INC. | $74.48 | 2023-2024 | Venclexta |
| Daiichi Sankyo INC. | $20.91 | 2024 | Vanflyta |
| Novartis Pharmaceuticals Corporation | $14.76 | 2025 | |
| Kite Pharma, INC. | $13.55 | 2025 | Yescarta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramzi Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.